Do you ever feel like you are in a losing battle with depression? Does depression impair your ability to work, manage your home, maintain close relationships, or participate in social outings? Have you tried multiple antidepressants, none of which seem to work?
You are not alone. In 2015, an estimated 10.3 million adults in the United States had at least one major depressive episode causing severe impairment. Here’s the thing: Not everyone who is depressed responds to standard treatments of antidepressants, therapy, etc.
If you are one of the many who have failed to respond to standard treatments, there is hope. Research shows that low doses of ketamine, administered intravenously (ketamin infusions), can rapidly relieve depressive symptoms.
Neuroscientist Rebecca Brachman shares breakthrough ketamine (“Calypsol”) treatment that may prevent mental disorders like depression and PTSD
NeuroMend Infusion Center is an Evidence-Based Center of Excellence, rooted in the recent scientific findings that low-dose ketamine infusions are effective in treating treatment-resistant depression (TRD). Through our work with TRD patients, we will use data we obtain to measure results, to further research, and to improve patient outcomes. NeuroMend Infusion Center is a learning organization, remaining abreast of the most recent science in mental health and expanding services as we learn and grow.